Potential to become a new modality in the treatment of ulcerative colitis offering prolonged remission without immune suppressionThe study which compared MB310, a precision microbiome medicine, with ...
New research has found that at-home gut microbiome tests lack standardization, resulting in different results from the same stool sample.
CAMBRIDGE - Microbiotica Ltd announced on Tuesday that its oral precision microbiome medicine MB310 demonstrated positive results in a Phase 1b trial for ulcerative colitis patients, meeting primary ...
Deep in the folds of the intestine, in microscopic pockets called crypts, a quiet surveillance system is always at work. Stem ...
A bacterial strain discovered frozen in an underground cave is resistant to 10 antibiotics, which could give scientists clues on preventing the rise of antimicrobial resistance.
What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and providers in The Beam, published monthly.
MB310, a live biotherapeutic developed by Cambridge-based Microbiotica, achieves 63% remission rate in early study IP Group PLC (LSE:IPO), the London-listed investor in science and technology ...
Morning Overview on MSN
How ultra-processed foods quietly wreck the gut microbiome?
Scientists are increasingly pointing to everyday ultra-processed foods as a quiet threat to the gut, linking industrial ...
The microbiome specialist, which for years has struggled to stay afloat, is cutting its staff by 30% and focusing resources on earlier, immunology-focused research.
(Alliance News) - IP Group PLC on Wednesday said portfolio company Microbiotica Ltd has announced positive results from a phase 1b first-in-human trail of MB310 in ulcerative colitis patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results